Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 16 of the 20 sources its claims cite were checked for support.

Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study

Open access
Wu, Chengrong, Pu, Qian, Zou, Yalin, Jin, Juan, Lei, Yu, Hu, Yaxin, Chen, Zhuo, Yu, Lei · 2025 · Scientific Reports

Abstract

Calcific aortic valve stenosis (CAVS) is steadily rising worldwide with no effective pharmacological agents available. Observational studies implicated dyslipidaemia as a risk factor for CAVS. Whether dyslipidaemia is causative for CAVS and the therapeutic potential of different lipid-modifying drug targets for CAVS treatment remains unclear. We appraised the relationship of genetically-proxied lipid traits and 12 lipid-modifying drug targets with CAVS risk using Mendelian randomization (MR). Genetic variants associated with lipid traits and variants in genes encoding lipid-modifying drug targets were retrieved from GLGC. Summary-level data for CAVS were obtained from the TARGET consortium and FinnGen. Validation analyses were performed using genetic instruments retrieved from liver-derived gene expression and circulation plasma levels of targets. Colocalisation and mediation analyses were performed to evaluate the robustness of our findings and explore potential mediators (i.e., lipoprotein a (Lp(a)), body mass index, apolipoprotein B (ApoB)). The MR analyses supported that total cholesterol and LDL-cholesterol level were independent causal risk factors. The drug-target MR analysis suggested that genetic mimicry of PCSK9 inhibition should reduce CAVS risk (OR = 0.63, 95% CI = 0.56-0.70), which was corroborated by colocalisation analysis. Secondary analyses supported a genetically proxied effect of liver-specific PCSK9 expression (OR = 0.94 per SD reduction in PCSK9 expression, 95% CI = 0.88-1.00) and circulating plasma levels of PCSK9 (OR = 0.86 per SD reduction in PCSK9 protein, 95% CI = 0.83-0.88) on CAVS risk. ApoB and Lp(a) mediated 55.9% and 4.5%, respectively, of the total effect of PCSK9 on CAVS risk. Multiple sensitivity analyses supported this observation. Our study supports total cholesterol, LDL-cholesterol as a causal factor for CAVS, and genetically proxied inhibition of PCSK9 may reduced its risk.

Overview

CoChat Summary

TL;DR

This Mendelian randomization study found that genetically higher total cholesterol and LDL-cholesterol are causal risk factors for calcific aortic valve stenosis (CAVS), while genetically proxied PCSK9 inhibition is associated with lower CAVS risk. Mediation analyses suggested the PCSK9 effect may act largely through ApoB rather than Lp(a).

Key findings

  • Genetically proxied 1-SD increases in total cholesterol and LDL-C were associated with higher CAVS risk: pooled OR = 1.65 (95% CI = 1.53–1.77) for TC and OR = 1.53 (95% CI = 1.42–1.65) for LDL-C. LDL-C remained an independent risk factor after adjusting for Lp(a) and BMI (OR = 1.41, 95% CI = 1.31–1.51), whereas the triglyceride association attenuated (OR = 1.09, 95% CI = 1.02–1.21).
  • Genetically proxied PCSK9 inhibition was associated with lower CAVS risk: pooled OR = 0.63 (95% CI = 0.56–0.70, P = 1.13 × 10−16) per SD reduction in LDL-C, with colocalization support (PP.H4 = 99.3%).
  • Secondary analyses supported PCSK9 effects using liver-specific expression (OR = 0.94 per SD reduction in PCSK9 expression, 95% CI = 0.88–1.00) and circulating plasma PCSK9 protein (OR = 0.86 per SD reduction, 95% CI = 0.83–0.88).
  • Mediation analysis estimated that ApoB mediated 55.9% and Lp(a) mediated 4.5% of the total effect of PCSK9 on CAVS risk.

Methods

  • Two-sample and multivariable Mendelian randomization using genetic instruments for lipid traits from GLGC, with CAVS outcome data from the TARGET consortium (13,765 cases) and FinnGen R11 (11,047 cases); the discussion reports 24,811 CAVS cases and 1,082,788 controls.
  • Drug-target MR examined 12 lipid-modifying targets, including PCSK9, using cis variants within ±100 kb of target genes; secondary analyses used cis-pQTLs from deCODE, Fenland, and UKB-PPP, and liver-derived cis-eQTLs from GTEx.
  • Analyses included colocalization, mediation via BMI, Lp(a), and ApoB, reverse MR, leave-one-out, and sensitivity analyses (weighted median, MR-Egger, weighted mode, MR-PRESSO), with Bonferroni-corrected significance thresholds.

Limitations

  • The paper states that horizontal pleiotropy cannot be definitively ruled out, although sensitivity and colocalization analyses were performed.
  • The authors note that genetic proxies represent lifelong per-SD changes and may not be equivalent to randomized controlled trial drug effects; no genome-wide significant cis-eQTL for PCSK9 was available, limiting power for expression analyses.
  • The paper states that gene-environment/gene-gene interactions, off-target effects, and nonlinearity could not be assessed from summary-level data, and all GWAS datasets were European ancestry, limiting generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41598-025-15525-4

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Study overview. # The genetic variants were oriented to be in the lipid increasing direction, i.e., effect estimates in Mendelian randomisation analysis was scaled to per SD increase in serum lipids.
Fig. 1 Study overview. # The genetic variants were oriented to be in the lipid increasing direction, i.e., effect estimates in Mendelian randomisation analysis was scaled to per SD increase in serum lipids.CC BY-NC-ND · PubMed Central
Fig. 2 Causal effects of genetically proxied lipids on calcific aortic valve stenosis.
Fig. 2 Causal effects of genetically proxied lipids on calcific aortic valve stenosis.CC BY-NC-ND · PubMed Central
Fig. 3 Results of multivariable Mendelian randomisation analysis of serum lipids and calcific aortic valve stenosis. (A) CAVS–LDL-C + Lp(a) + BMI. (B) CAVS–TG + Lp(a) + BMI.
Fig. 3 Results of multivariable Mendelian randomisation analysis of serum lipids and calcific aortic valve stenosis. (A) CAVS–LDL-C + Lp(a) + BMI. (B) CAVS–TG + Lp(a) + BMI.CC BY-NC-ND · PubMed Central
Fig. 4 Genetic colocalization between PCSK9 and calcific aortic valve stenosis risk. (A) Colocalisation between LDL-C and calcific aortic valve stenosis in the PCSK9 region. (B) Colocalization analyses of cis-pQTL from deCODE for PCSK9. (C) Colocalization analyses of cis-pQTL from Fenland for PCSK9. (D) Colocalization analyses of cis-pQTL from UKB-PPP for PCSK9.
Fig. 4 Genetic colocalization between PCSK9 and calcific aortic valve stenosis risk. (A) Colocalisation between LDL-C and calcific aortic valve stenosis in the PCSK9 region. (B) Colocalization analyses of cis-pQTL from deCODE for PCSK9. (C) Colocalization analyses of cis-pQTL from Fenland for PCSK9. (D) Colocalization analyses of cis-pQTL from UKB-PPP for PCSK9.CC BY-NC-ND · PubMed Central
Fig. 5 External validation of the causal relationship between PCSK9 and calcific aortic valve stenosis using data from (A) cis-eQTL and (B) cis-pQTLs.
Fig. 5 External validation of the causal relationship between PCSK9 and calcific aortic valve stenosis using data from (A) cis-eQTL and (B) cis-pQTLs.CC BY-NC-ND · PubMed Central
Fig. 6 Mediation analysis of the effect of genetically proxied PCSK9 inhibition on calcific aortic valve stenosis via potential mediators.
Fig. 6 Mediation analysis of the effect of genetically proxied PCSK9 inhibition on calcific aortic valve stenosis via potential mediators.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

9 Valid · 0 Not valid · 1 Not checked · 66 Own results and interpretations

51 more claims

Create a free account to see all 76 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 12
  • It may state two separate claims as one. 11

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 55 references

Cited by

See all 3

Metadata

Authors
Wu, C., Pu, Q., Zou, Y., Jin, J., Lei, Y., Hu, Y., Chen, Z., & Yu, L.
Affiliations
  • Affiliated Hospital of Guizhou Medical University (CN)
  • Guizhou University (CN)
Corresponding author
  • Lei, Yu
  • Chen, Zhuo
  • Yu, Lei
Venue
Scientific Reports
Published
2025-08-12
Volume
15
Issue
1
Pages
29475-29475
ISSN
2045-2322 (ISSN-L)
OpenAlex
W4413112637
Cited by
3
References
55
Citations by year
2026: 3
FWCI
2.08
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
calcific aortic stenosis, dyslipidemia, PCSK9 inhibition, total cholesterol, LDL cholesterol, apolipoprotein B, lipoprotein(a), causal risk factors, mediation analysis, colocalization, genetic instruments
MeSH terms
Proprotein Convertase 9, Aortic Valve, Aortic Valve Stenosis, Apolipoproteins B, Calcinosis, Humans, Lipids, Cholesterol, LDL, Risk Factors, Lipoprotein(a), Polymorphism, Single Nucleotide, Dyslipidemias, Mendelian Randomization Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study. https://app.cochat.ai/papers/10.1038/s41598-025-15525-4
The paper
Wu, C., Pu, Q., Zou, Y., Jin, J., Lei, Y., Hu, Y., Chen, Z., & Yu, L. (2025). Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study. Scientific Reports. https://doi.org/10.1038/s41598-025-15525-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.